Wall Street analysts expect that UroGen Pharma Ltd. (NASDAQ:URGN) will announce $17.20 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for UroGen Pharma’s earnings, with estimates ranging from $16.50 million to $17.90 million.